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It is accepted that individual susceptibility plays an important 
aetiopathogenic role in tuberculosis (TB) depending on 
the immunological strength of the person infected by 
Mycobacterium tuberculosis.1 The susceptibility might be genetic, 
acquired or both, but it is always expressed in the metabolism 
of the individual. The wasting syndrome present in many TB 
patients suggests an impaired insulin/glucose metabolism on 
the basis that insulin is a hormone of universal action, the main 
growth factor in the human body, and glucose qualitatively the 
main fuel.2
Various experimental methods and modelling approaches 
have been developed to assess the metabolism of insulin and 
glucose in humans.3 The oral glucose tolerance test (OGTT) is 
a very useful tool because of its simplicity and the reliability of 
the physiological and biochemical characteristics of the patient. 
Although the abovementioned modelling relates mainly to the 
diagnosis and assessment of diabetes, impaired insulin/glucose 
metabolism may occur in other pathological states too, and the 
same methodology can be applied to assess the insulin/glucose 
profile in these cases. Borderline diabetes has been reported 
in TB cases4 and diabetes has also been considered a risk 
factor for TB.5 Some other metabolic derangements have also 
been reported in TB.6 The question is whether the metabolic 
derangements are part of the clinical course of the disease, or 
whether people with these types of metabolic derangements 
are prone to TB. 
It is well known that only 5 - 6% of people infected with 
M. tuberculosis develop the disease,7 which is clear evidence 
that individual susceptibility plays an important role in the 
aetiopathogenesis of TB. It is not clear which part of the 
defence system is damaged or weakened in those people. 
The relationship between impaired cellular immunology 
and impaired insulin function has also been reported.8,9 This 
article reports on a study of the OGTT in untreated TB patients 
compared with a matched control group.
Material and methods
Sixty-three untreated TB patients were recruited from the 
Mthatha General Hospital pulmonary clinic; these patients 
came to the clinic with the classic symptoms of TB and the 
condition was confirmed by sputum analysis. The subjects 
were studied and compared with 89 apparently healthy 
sex- and age-matched volunteers as the control population. 
Height and weight were determined using an electronic 
scale. Standard OGTTs were performed in both groups in 
the morning (07h00 - 08h00) after an overnight fast.  Blood 
samples were taken from the antecuvital vein in a vacutainer 
with sodium fluoride/potassium oxalate as anticoagulant 
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Objective. To examine glucose tolerance in sputum-positive 
non-treated pulmonary tuberculosis (TB) patients as part of a 
general metabolic profile.
Subjects. Sixty-three sputum-positive non-treated patients (male 
and female) attending the pulmonary clinic at Mthatha General 
Hospital in the Eastern Cape and 89 apparently healthy sex-
and age-matched volunteers.
Methods. Sixty-three untreated TB patients who came to the 
Mthatha General Hospital’s pulmonary clinic with classic 
symptoms of TB, confirmed by sputum analysis, were 
recruited for the study. Eighty-nine apparently healthy sex-
and age-matched volunteers served as the control group. 
Anthropometric measurements were taken using an electronic 
scale. Standard oral glucose tolerance tests (OGTTs) were 
performed in both groups in the morning after an overnight 
fast. Anticoagulant-treated blood was analysed for glucose 
and insulin using Peridochrome Glucose (Boehringer 
Mannheim, Mannheim, Germany) and radioimmunoassay 
(RIA) (Diagnostic Products Corporation, Los Angeles, USA) 
respectively.
Results. There was sluggish response to glucose and insulin 
in the TB patient group compared with the control group. 
Glucose and insulin levels were significantly higher in patients 
at 0, 30, 60, 120, and 180 minutes. Analysis of variance gave the 
following p-values, viz. p = 0.0000, 0.0004, 0.0000, 0.0000 and 
0.0000 for glucose, and p = 0.0317, 0.0071, 0.0000, 0.0005 and 
0.0000 for insulin respectively. 
Conclusions. The results of this study suggest an altered 
glucose/insulin metabolism in TB patients. This might play an 
important role in the clinical course of the disease.
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(Vacutainer System, Becton Dickinson, Plymouth, UK) 
following the aseptic rules at 0, 30, 60, 120 and 180 minutes. 
Glucose levels in plasma were determined within 3 hours. 
Plasma for insulin testing was kept frozen (- 20oC) until 
analysed. Seventy-five grams of glucose dissolved in 300 
ml drinking water were given orally to each patient and 
to controls. Glucose was determined colorimetrically 
(Peridochrome Glucose, Boehringer Mannheim) using 
a Photometer 5010. Insulin level was determined by 
radioimmunoassay (RIA) (Coat-A-Count Insulin Diagnostic 
Products Corporation, Los Angeles, USA). Multivalent Control 
Module CONS6 was used as an external explorer sample. 
Data were analysed with Statistica-5, applying non-parametric 
methods whenever necessary. Patients were tested for HIV 
(IMX Abbott Diagnostic Division, Wiesbaden, Germany) with 
the patients’ consent.
Results
Results of the OGTT and insulin tests for patients and controls 
are presented in Figs 1 and 2. Glucose and insulin levels were 
found to be higher in patients than controls. Glucose peak 
was delayed for patients compared with controls. Further, it 
can be seen that glucose did not return to basal level in the 
patient group compared with controls. This was statistically 
significant for all 5 sampling times in a point-to-point analysis 
of variance (ANOVA) (breakdown and one-way ANOVA,  
p = 0.0000, 0.0000, 0.0000, 0.0000, 0.000). With regard to insulin 
(Fig. 2) the pattern was more or less similar, with a delayed 
peak compared with controls and non-return to basal level 
in a point-to-point ANOVA (Kruskal-Wallis ANOVA median 
test, p = 0.0317, 0.0071, 0.0005, 0.0000, 0.0000). As expected, 
basal glucose distribution was normal and insulin log-normal 
(Fig. 3). The correlation between glucose and log-insulin was 
essentially different between TB patients and controls. As 
expected, in the normal population there was no correlation 
between plasma glucose and plasma log-insulin, while the 
figure was totally different in the patient group (Tables I 
and II). There was a positive correlation between these two 
metabolites (glucose/log-insulin). This might be an indication 
that these patients were in a critical metabolic state. Thirty-
two per cent of patients were confirmed HIV-positive and 
there was no significant statistical difference in any of the 
parameters between HIV-positive and negative patients. There 
was a significant difference in body mass index (BMI) values, 
viz. 19.58 and 23.80 for patients and controls respectively (p = 
0.0000, analysis of variance, breakdown and one-way ANOVA).
Discussion
The results obtained clearly show a sluggish OGTT for both 
glucose and insulin suggesting a partial glucose intolerance 
and also the possibility of a certain insulin dysfunction in the 
patient group compared with the control group. The normal 
OGTT is based on the absorption of glucose, which should 
peak in blood at 20 - 40 minutes, returning to basal level at 
90 minutes.6 Insulin secretion is triggered by increased level 
of glucose in blood plus some other intestinal factors.10 The 
insulin level should peak in blood at 30 - 40 minutes and 
should return to basal level at 180 minutes. Anything different 
from this pattern tends to be associated with pathological 
events. A flat pattern expresses improper intestinal-pancreatic 
physiology or diabetic-like state due to improper glucose and 
insulin uptake by the peripheral tissues. It has been established 
that a value above 7.8 mmol/l or 11.1 mmol/l of blood glucose 
at 120 minutes after oral glucose load is considered intolerant 
or diabetic.11 But between ‘diabetic’ or ‘intolerant’ and normal 
there is a gap, which looks to be associated with several 
pathological states (silent killer).12 
Glucose has been evolutionally selected as the main fuel 
for all type of cells; without it there is no proper biology in 
humans. Insulin, on the other hand, has been selected as the 
main growth factor in the body.2,13 Unfortunately for most 
Fig. 1. Point-to-point analysis of variance (breakdown and one-way 
ANOVA) of glucose level (mean ± standard deviation (SD)) between un-
treated TB patients and the control group (p = 0.000, 0.000, 0.000, 0.000 
and 0.0000) respectively for 0, 30, 60, 120 and 180 minutes.
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Fig. 2. Point-to-point analysis of variance (Kruskal-Wallis ANOVA me-
dian test) of insulin level (mean ± standard error (SE)) between untreated 
TB patients and the control group (p = 0.0317, 0.0071, 0.005, 0.0000 and 
0.0000) respectively for 0, 30, 60, 120 and 180 minutes.
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people its only role is the glucose uptake by the tissues, but 
the main role of insulin is intracellular with non-genomic 
or genomic actions.14,15 The half-life of insulin in plasma in 
humans is 6 - 8 minutes.16 As such the delayed clearance of 
insulin in blood that we observed in the TB group suggests an 
impaired insulin internalisation or insulin resistance, which 
causes an improper intracellular action of this hormone. 
Furthermore the positive correlation between glucose level in 
plasma and log-insulin in plasma suggests that those patients 
are in a critical metabolic state. In any normal population there 
is usually no correlation between fasting insulin and fasting 
glucose levels in plasma, but if any correlation is expected 
according to the insulin mechanism of action, it should be a 
negative correlation, more insulin less glucose in plasma or 
more glucose less insulin. This positive correlation is another 
suggestion that those patients are in an insulin resistance state. 
The relation between insulin action 
and the immunological mechanism of 
macrophages and lymphocytes has been 
well documented. It has been reported 
that insulin exerts a very strong effect on 
macrophage action by increasing pyruvate 
dehydrogenase (PDH) complex activity 
and some other enzymes that play an 
important role in their phagocyte capacity.17 
The same has also been found with regard 
to lymphocytes.18,19 The mechanism of TB 
infection and the difference between normal 
persons and those prone to developing TB 
depend precisely on the improper function 
of macrophages, lymphocytes or both.20 In a 
normal person infected with M. tuberculosis, 
macrophages and phagocytes are initially 
unable to destroy the bacteria. After some 
time sensitised lymphocytes attract and 
activate macrophages, which acquire a 
greatly enhanced phagocyte and destructive 
capability, destroying most of the micro-organism and forming 
the characteristic micro-granuloma. In this way the infection 
is arrested.20 The difference between being susceptible to TB 
or not probably depends on proper lymphocyte sensitisation/
macrophage activation. 
The factors regulating this immunological process should 
also be the target of therapeutic action in TB cases. It seems 
that insulin and glucose metabolism might play an important 
role in the process of lymphocyte sensitisation and macrophage 
activation. If the glucose-insulin metabolism is altered it 
can be expected that lymphocyte and macrophage function 
will also be altered, allowing the pathological course of TB. 
Unfortunately most therapeutic TB interventions are directed 
against the biology of the bacteria, with very little currently 
being done to restore host biology. 
Fig. 3. Distribution of fasting glucose (normal) and insulin (log-normal) (A1= glucose; A2 = 
insulin (patient); B1 = glucose; B2 = insulin (control)).
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Table I. Correlation coefficient (r) between glucose and log-insulin during the OGTT 
Variable    Log-insulin 0 Log-insulin 30 Log-insulin 60  Log-insulin 120 Log-insulin 180
Control group
Glu0       -0.13         0.10         0.13           0.01         -0.13
Glu30       -0.14         0.04         0.09           0.07          0.04
Glu60       -0.13        -0.01         0.06           0.08         -0.14
Glu120       -0.11        -0.27*         0.06           0.16         -0.11
Glu180        0.08        -0.23         0.04          -0.05          0.07
TB patients
Glu0        0.50*         0.16         0.08           0.25          0.27*
Glu30        0.14         0.33*         0.35*           0.39*         0.19
Glu60       -0.04         0.08         0.30*           0.43*         0.29*
Glu120       -0.10        -0.02         0.08           0.29*                 0.33*
Glu180       -0.03        -0.20        -0.12           0.12          0.49*
* Statistical significance at least p < 0.05.
Glu = glucose.
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The results of the present study strongly suggest that insulin-
glucose metabolism is altered in TB patients. It has also been 
reported that a diabetic-like state is present in TB patients.4 On 
the other hand impaired glucose tolerance secondary to TB has 
also been reported.21 The immediate question is whether this 
metabolic derangement is characteristic of TB pathophysiology, 
or whether people with this derangement are prone to TB.  We 
believe that according to the aetiopathogenesis of the disease in 
which a poor immune response in the host plays an important 
role, the most logical explanation is that people with this 
derangement are prone to TB. Most importantly, in the battle 
against TB and increasing multidrug resistance the philosophy 
of solving this metabolic derangement should be introduced in 
the hope that it might improve host immunological strength, 
favouring the patients’ total cure and offering less chance of 
multi-drug resistance. 
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Table II. Descriptive statistics for glucose and insulin at different points during the OGTT                                          
   Mean      Standard deviation   Standard error 
TB patients 
Glu0                  4.94148               0.69577         0.089085
Glu30   6.98233                            1.28118        0.165400
Glu60   7.17017                            1.92479        0.248490
Glu120   6.17705                            1.69297        0.216762
Glu180   5.11131                            1.61673        0.207001
Insu0    6.95377                            4.11277        0.526586
Insu30                 24.43700            17.11464        2.209491
Insu60                 31.64783            25.44571        3.285027
Insu120  25.63600            18.28743        2.360897
Insu180     15.83131            12.88091        1.649232
Controls                                               
Glu0   4.48975            0.40679        0.045480
Glu30   5.79064            1.20409        0.136337
Glu60   5.09532            1.24968        0.142414
Glu120   4.41152            0.69346        0.078021
Glu180   3.46987             0.75367        0.085336
Insu0   5.75789            2.45801        0.269801
Insu30   17.55458            13.64728        1.497983
Insu60   16.86220            10.69280        1.180823
Insu120  13.31384            9.35090        1.032634
Insu180  7.55031            7.50920        0.839554
Glu = glucose; Insu = insulin.
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